Methods of Treatment with Anti-Factor XI/XIa Antibodies
Summary
The European Patent Office published Novartis AG's patent application EP3558370A2 for methods of treating conditions using anti-Factor XI/XIa antibodies. The patent names three inventors (Friedman, Khder, Lefkowitz) and covers therapeutic applications designated for all European Patent Convention states including DE, FR, GB, IT, ES, NL, and others.
What changed
The European Patent Office published EP3558370A2, granting Novartis AG exclusive rights to methods of treatment using anti-Factor XI/XIa antibodies. The patent falls under IPC classifications A61K 39/44 and A61P 7/02, covering therapeutic applications for hemostasis-related conditions.\n\nPharmaceutical and biotechnology companies developing Factor XI/XIa inhibitors or anticoagulant therapies should evaluate this patent for potential freedom-to-operate concerns in European markets. Competitors may need to seek licensing arrangements or design around the protected antibody sequences and treatment methods.
What to do next
- Review freedom-to-operate for Factor XI/XIa programs
- Monitor patent validity challenges
Archived snapshot
Apr 8, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIES
Publication EP3558370A2 Kind: A2 Apr 01, 2026
Applicants
Novartis AG
Inventors
FRIEDMAN, Carola, KHDER, Yasser, LEFKOWITZ, Martin
IPC Classifications
A61K 39/44 20060101AFI20190619BHEP A61P 7/02 20060101ALI20190619BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.